Insight
ASCO
Collage of G Curigliano and Aditya Bardia

DESTINY-Breast06 is the first study to investigate a HER2-directed therapy in patients with HER2-ultralow tumors – ASCO

ASCO shared a post on X:

“Experts Giuseppe Curigliano & Aditya Bardia discuss the results of the DESTINY-Breast06 trial, which showed significant PFS improvement with T-DXd in pts with HR+, HER2-low metastatic.”

DESTINY-Breast06 Shows Significant PFS Improvement With T-DXd for HR-Positive Metastatic Breast Cancer. How Do These Results Impact Practice for All Patients?

Authors: Giuseppe Curiglian and Aditya Bardia

DESTINY-Breast06 is the first study to investigate a HER2-directed therapy in patients with HER2-ultralow tumors - ASCO

Source: ASCO/X

Aditya Bardia ASCO Breast Cancer cancer cancer awareness cancer care DESTINY-Breast06 fight against cancer Giuseppe Curigliano Global fight against cancer OncoDaily Oncology